missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Denosumab Recombinant Human Monoclonal Antibody
Human Recombinant Monoclonal Antibody
Brand: Invitrogen™ MA541845
This item is not returnable.
View return policy
Description
Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and 2 light chains. Each light chain consists of 215 amino acids. Each heavy chain consists of 448 amino acids with 4 intramolecular disulfides. FDA approved on June 1, 2010.
Specifications
| Denosumab | |
| Recombinant Monoclonal | |
| Unconjugated | |
| AMG162; Prolia | |
| Human TNFSF11/CD254. | |
| 100 μg | |
| Primary | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Liquid | |
| Chemical |
| ELISA, SDS-Page | |
| 1.73 mg/mL | |
| PBS with no preservative; pH 7.4 | |
| Human | |
| Protein A | |
| RUO | |
| Human | |
| Antibody | |
| IgG2 κ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction